Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30,284,111
-
Total 13F shares
-
17,520,689
-
Share change
-
+776,150
-
Total reported value
-
$659,108,717
-
Price per share
-
$37.62
-
Number of holders
-
100
-
Value change
-
+$33,180,521
-
Number of buys
-
55
-
Number of sells
-
34
Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q3 2022
As of 30 Sep 2022,
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) was held by
100 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,520,689 shares.
The largest 10 holders included
FMR LLC, ORBIMED ADVISORS LLC, BlackRock Inc., ALKEON CAPITAL MANAGEMENT LLC, STATE STREET CORP, VANGUARD GROUP INC, Nantahala Capital Management, LLC, First Light Asset Management, LLC, CITIGROUP INC, and CITADEL ADVISORS LLC.
This page lists
102
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.